Drug Landscape ›
Fluticasone Diskus ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 11
Most-reported reactions
Influenza Like Illness — 2 reports (18.18%) Arthralgia — 1 report (9.09%) Drug Ineffective — 1 report (9.09%) Enterococcal Infection — 1 report (9.09%) Erythema — 1 report (9.09%) Escherichia Sepsis — 1 report (9.09%) Feeling Hot — 1 report (9.09%) Inflammation — 1 report (9.09%) Neuralgia — 1 report (9.09%) Pain In Extremity — 1 report (9.09%)
Source database →
Fluticasone Diskus in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Fluticasone Diskus approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Fluticasone Diskus in United States?
Johns Hopkins University is the originator. The local marketing authorisation holder may differ — check the official source linked above.